CN113663137A - Composite biological patch and preparation method and application thereof - Google Patents
Composite biological patch and preparation method and application thereof Download PDFInfo
- Publication number
- CN113663137A CN113663137A CN202110964615.6A CN202110964615A CN113663137A CN 113663137 A CN113663137 A CN 113663137A CN 202110964615 A CN202110964615 A CN 202110964615A CN 113663137 A CN113663137 A CN 113663137A
- Authority
- CN
- China
- Prior art keywords
- solution
- collagen
- repair
- composite biological
- acid solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002131 composite material Substances 0.000 title claims description 44
- 238000002360 preparation method Methods 0.000 title claims description 40
- 239000000243 solution Substances 0.000 claims description 172
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 69
- 230000002209 hydrophobic effect Effects 0.000 claims description 63
- 102000008186 Collagen Human genes 0.000 claims description 55
- 108010035532 Collagen Proteins 0.000 claims description 55
- 229920001436 collagen Polymers 0.000 claims description 55
- 239000001856 Ethyl cellulose Substances 0.000 claims description 45
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 45
- 230000008439 repair process Effects 0.000 claims description 45
- 229920001249 ethyl cellulose Polymers 0.000 claims description 44
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 44
- 210000001361 achilles tendon Anatomy 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 38
- 239000012528 membrane Substances 0.000 claims description 37
- 102000012422 Collagen Type I Human genes 0.000 claims description 35
- 108010022452 Collagen Type I Proteins 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 34
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 29
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 29
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 29
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 29
- 230000002924 anti-infective effect Effects 0.000 claims description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 229920002678 cellulose Polymers 0.000 claims description 21
- 239000001913 cellulose Substances 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000012266 salt solution Substances 0.000 claims description 17
- 239000003929 acidic solution Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 229940088598 enzyme Drugs 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 15
- 238000004108 freeze drying Methods 0.000 claims description 14
- 241000283690 Bos taurus Species 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 229920001046 Nanocellulose Polymers 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 12
- 238000003825 pressing Methods 0.000 claims description 12
- 239000004365 Protease Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 210000000513 rotator cuff Anatomy 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 206010019909 Hernia Diseases 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 7
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 7
- 229960000991 ketoprofen Drugs 0.000 claims description 7
- 108090000284 Pepsin A Proteins 0.000 claims description 6
- 102000057297 Pepsin A Human genes 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940111202 pepsin Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 3
- 108010004032 Bromelains Proteins 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 108010022355 Fibroins Proteins 0.000 claims description 3
- 108090000270 Ficain Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 108090000526 Papain Proteins 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 241000187392 Streptomyces griseus Species 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 3
- 229960003022 amoxicillin Drugs 0.000 claims description 3
- 235000019835 bromelain Nutrition 0.000 claims description 3
- 229960003405 ciprofloxacin Drugs 0.000 claims description 3
- 235000019836 ficin Nutrition 0.000 claims description 3
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 229960005224 roxithromycin Drugs 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 108090000787 Subtilisin Proteins 0.000 claims description 2
- 238000010041 electrostatic spinning Methods 0.000 claims description 2
- 229940030225 antihemorrhagics Drugs 0.000 claims 1
- 230000000025 haemostatic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 28
- 238000009987 spinning Methods 0.000 description 24
- 238000003756 stirring Methods 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 14
- 238000007710 freezing Methods 0.000 description 11
- 230000008014 freezing Effects 0.000 description 11
- 230000017423 tissue regeneration Effects 0.000 description 9
- 239000002121 nanofiber Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000002418 meninge Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 239000013557 residual solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011265 semifinished product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- -1 but not limited to Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000000887 face Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000021970 Abdominal wall defect Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710135785 Subtilisin-like protease Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/04—Materials or treatment for tissue regeneration for mammary reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/10—Materials or treatment for tissue regeneration for reconstruction of tendons or ligaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/12—Materials or treatment for tissue regeneration for dental implants or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/30—Materials or treatment for tissue regeneration for muscle reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention provides a composite biological patch and a preparation method and application thereof, and relates to the technical field of medical treatment. The composite biological patch provided by the invention comprises a hydrophobic porous layer, a compact layer and a porous support, wherein the hydrophobic porous layer is back to one side of a tissue to be repaired and is loaded with anti-infective drugs, and the hydrophobicity of the hydrophobic porous layer and the loaded drugs can be matched with each other, so that the composite biological patch is beneficial to slow release of the drugs and plays roles of preventing and resisting infection and preventing adhesion; the porous scaffold has a porous structure, faces one side of the tissue to be repaired, is beneficial to the adhesion and growth of cells and induces the regeneration of membrane tissue; the hydrophobic porous layer and the porous support are separated by the compact layer, so that the dimensional stability and the mechanical strength of a product can be ensured, and meanwhile, the function of a barrier can be played. The composite biological patch provided by the invention can be used for meninges repair, rotator cuff repair, hernia repair, ophthalmologic repair, breast repair, hemostatic repair or oral repair.
Description
Technical Field
The invention relates to the technical field of medical treatment, in particular to a composite biological patch and a preparation method and application thereof.
Background
The repair and regeneration of human defective tissues are always difficult problems in clinic. In recent years, with the development of cell biology and tissue engineering technology, a new repair material, namely a biological patch, is receiving attention. The biological patch is a material which is derived from homologous or heterologous biological tissues, removes various cells contained in the tissues through treatment processes such as decellularization and the like to completely preserve the three-dimensional structure of extracellular matrix and can be used for repairing damaged soft tissues of a human body. The biological patch can repair damaged tissues through space induction and tissue replacement, and has good tissue compatibility. Collagen is an extracellular matrix, a biologically functional structural protein, 1/3 which accounts for the total amount of human proteins, and is a major component constituting connective tissues or organs such as skin, ligaments, cartilage, and tendons. As a biomedical material, collagen has excellent properties such as weak immunoantigenicity, good biodegradability, and promotion of cell survival and growth. Therefore, the collagen basement membrane patch is widely applied to the aspects of dural membrane defect repair, motor tendon laceration repair, hernia and abdominal wall defect repair, burn plastic, oral cavity membrane defect repair and the like.
At present, the main material sources of the collagen-based patch comprise an allogeneic material and a xenogeneic material, and the allogeneic material is not suitable for clinical application because the material sources are easily limited, protein viruses easily exist and the price is relatively expensive. The xenogenic materials comprise pigskin, pig small intestine, bovine pericardium, bovine achilles tendon and the like, and the natural materials are derived from tissues of pigs, cows and the like, so the natural materials have rich resources, low cost, small toxicity after treatment and good biocompatibility, and therefore, the biological patch prepared by the raw materials has wide application prospect. However, the current biological patches have the following disadvantages: firstly, the general mechanical property is not ideal enough, in order to ensure the mechanical strength of the patch, a chemical crosslinking method is mostly adopted for modification, solvent residue is easy to occur, and the biocompatibility and the safety of the patch cannot be ensured; the animal tissues are directly treated and then repaired, such as pigskin, pericardium and the like, so that the plaster is poor in adhesion and easy to shift; and fourthly, the porous structure is not suitable, so that the tissue regeneration performance is not good.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
A first object of the present invention is to provide a composite biological patch to solve at least one of the above problems.
The second purpose of the invention is to provide a preparation method of the composite biological patch, which is simple and convenient and has low cost.
The third purpose of the invention is to provide the application of the composite biological patch in meninges repair, spinal cord repair, rotator cuff repair, hernia repair, ophthalmology repair, breast repair, hemostasis repair or oral repair.
In a first aspect, the present invention provides a composite biological patch comprising a hydrophobic porous layer, a dense layer and a porous scaffold;
the hydrophobic porous layer is back to one side of the tissue to be repaired and is loaded with anti-infective drugs;
the side of the porous bracket facing the tissue to be repaired;
the dense layer is located between the hydrophobic porous layer and the porous scaffold.
As a further technical scheme, the raw material for preparing the hydrophobic porous layer comprises hydrophobic nano-cellulose;
preferably, the hydrophobic nanocellulose comprises ethylcellulose.
As a further technical scheme, the preparation method of the hydrophobic porous layer comprises the following steps:
dissolving hydrophobic nano-cellulose in an organic reagent, adding an anti-infective drug, and preparing a membrane after mixing;
preferably, the organic reagent comprises hexafluoroisopropanol and/or ethanol;
preferably, the ratio of the hydrophobic nanocellulose to the organic reagent is 1g (4-8) mL;
preferably, the anti-infective drug is added in an amount of 5-10% of the hydrophobic nano-cellulose in percentage by mass;
preferably, the film-making manner comprises electrostatic spinning;
preferably, the thickness of the hydrophobic porous layer is 0.5-2 mm.
As a further technical scheme, the preparation material of the compact layer comprises ethyl cellulose and/or hydroxypropyl methyl cellulose.
According to a further technical scheme, the preparation material of the porous scaffold comprises at least one of type I collagen, cellulose, chitosan, hyaluronic acid, gelatin, silk fibroin and starch, and preferably the type I collagen.
As a further technical scheme, the preparation method of the porous scaffold comprises the following steps:
dissolving the type I collagen in an acid solution to obtain a collagen solution, and then drying to prepare a porous scaffold;
preferably, the acidic solution comprises an acetic acid solution and/or a hydrochloric acid solution, preferably an acetic acid solution;
preferably, the concentration of the acetic acid solution is 0.01-1mol/L, preferably 0.02-0.5 mol/L;
preferably, the concentration of the type I collagen in the collagen solution is 0.1 wt% to 2.0 wt%, preferably 0.5 wt% to 1.5 wt%;
preferably, the manner of drying comprises freeze drying;
preferably, the freeze-drying conditions are as follows: treating at-40 deg.c to-10 deg.c for 1-6 hr, treating at-10 deg.c to-0 deg.c for 12-48 hr, and treating at 22 deg.c to 28 deg.c for 1-2 hr.
As a further technical scheme, the preparation method of the type I collagen comprises the following steps:
a. removing impurities from the Achilles tendon of the animal, crushing, and then carrying out salt solution treatment;
b. treating the animal achilles tendon treated in the step a with enzyme, and removing insoluble substances;
c. b, adjusting the pH value of the solution obtained in the step b to 12-14, and adding a salt solution until the salt concentration in the solution is 2.5-7.5mol/L to obtain a precipitate;
d. c, sequentially treating the precipitate obtained in the step c with an acidic solution, separating and drying to obtain type I collagen;
preferably, the animal achilles tendon comprises at least one of bovine achilles tendon, porcine achilles tendon, equine achilles tendon and ovine achilles tendon, preferably bovine achilles tendon;
preferably, in step a, the salt solution comprises NaCl solution and NaHCO solution3At least one of solution, sodium citrate solution, Tris-HCl solution and Tris-Base solution, preferably NaCl solution;
preferably, in the step a, the concentration of the salt solution is 5 wt% to 25 wt%;
preferably, in the step a, the mass ratio of the animal achilles tendon to the saline solution is 1 (50-100);
preferably, in the step b, the enzyme treatment is to treat the animal achilles tendon with an acid solution containing enzyme;
preferably, in the step b, the enzyme comprises at least one of pepsin, trypsin, ficin, bromelain, papain, streptomyces griseus secretase and subtilisin, and is preferably pepsin;
preferably, in the step b, the acidic solution comprises at least one of an acetic acid solution, a citric acid solution, a malic acid solution and a lactic acid solution, and is preferably an acetic acid solution;
preferably, in the step b, the concentration of the acid solution is 0.25-0.8 mol/L;
preferably, in step c, the pH of the solution obtained in step b is adjusted by using alkali solution, wherein the alkali comprises NaOH, KOH, Ca (OH)2Preferably NaOH;
preferably, in the step c, the pH value of the solution obtained in the step b is adjusted to 13, and a salt solution is added until the salt concentration in the solution is 4-5 mol/L;
preferably, in the step d, the acidic solution includes at least one of a hydrochloric acid solution, an acetic acid solution, a citric acid solution, a phosphoric acid solution and a sulfuric acid solution, and is preferably a hydrochloric acid solution;
preferably, in step d, the concentration of the acidic solution is 0.1-10mol/L, preferably 2-5 mol/L.
As a further technical scheme, the anti-infective drug comprises at least one of ketoprofen, roxithromycin, amoxicillin or ciprofloxacin.
In a second aspect, the invention provides a preparation method of a composite biological patch, which comprises the following steps:
mixing an organic reagent dissolved with ethyl cellulose and a hydroxypropyl methyl cellulose aqueous solution, then coating the mixed solution between the hydrophobic porous layer and the porous bracket, pressing, and heating to obtain a composite biological patch;
preferably, the organic reagent comprises ethanol;
preferably, the concentration of ethyl cellulose in the organic reagent is 2 wt% to 5 wt%;
preferably, the concentration of the hydroxypropyl methyl cellulose aqueous solution is 2 wt% -5 wt%;
preferably, the volume ratio of the organic reagent dissolved with the ethyl cellulose to the hydroxypropyl methyl cellulose aqueous solution is 1 (10-15);
preferably, the pressure of the pressing is 0.4-0.8 MPa;
preferably, the pressing time is 40-60 min;
preferably, the temperature of the heating treatment is 110-;
preferably, the time of the heat treatment is 24-36 h;
preferably, the thickness of the mixed solution coating is 0.1-0.5 mm;
preferably, the thickness of the composite biological patch is 2-5 mm.
In a third aspect, the invention provides a composite biological patch for meninges repair, spinal membrane repair, rotator cuff repair, hernia repair, ophthalmic repair, breast repair, hemostatic repair or oral repair.
Compared with the prior art, the invention has the following beneficial effects:
the composite biological patch provided by the invention comprises a hydrophobic porous layer, a compact layer and a porous support, wherein the hydrophobic porous layer is back to one side of a tissue to be repaired and is loaded with anti-infective drugs, and the hydrophobicity of the hydrophobic porous layer and the loaded drugs can be matched with each other, so that the composite biological patch is beneficial to slow release of the drugs and plays roles of preventing and resisting infection and preventing adhesion; the porous scaffold has a porous structure, faces one side of the tissue to be repaired, is beneficial to the adhesion and growth of cells and induces the regeneration of membrane tissue; the hydrophobic porous layer and the porous support are separated by the compact layer, so that the dimensional stability and the mechanical strength of a product can be ensured, and meanwhile, the function of a barrier can be played.
The preparation method of the composite biological patch provided by the invention is simple and convenient, and has low cost.
The composite biological patch provided by the invention can be used for meninges repair, rotator cuff repair, hernia repair, ophthalmologic repair, breast repair, hemostatic repair or oral repair.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 is a graph of the drug release rates of the membrane patches of examples 1-3 and comparative example 3;
FIG. 2 is a graph of the membrane patch staining of example 1;
figure 3 is a graph of the membrane patch staining of comparative example 3.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to embodiments and examples, but those skilled in the art will understand that the following embodiments and examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. Those who do not specify the conditions are performed according to the conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The composite biological patch can be used as a meninges patch, a rotator cuff patch, a hernia patch, an ophthalmological patch, a breast patch, a hemostatic patch or an oral cavity repairing film, wherein the side back to the tissue to be repaired in the invention refers to the side back to the meninges, the rotator cuff, the oral cavity film and other defective tissues; the side facing the tissue to be repaired is the side facing other defected tissues such as meninges, spinal cord membrane, rotator cuff, oral cavity membrane and the like.
In a first aspect, the present invention provides a composite biological patch comprising a hydrophobic porous layer, a dense layer and a porous scaffold;
the hydrophobic porous layer is back to one side of the tissue to be repaired and is loaded with anti-infective drugs;
the side of the porous bracket facing the tissue to be repaired;
the dense layer is located between the hydrophobic porous layer and the porous scaffold.
The composite biological patch provided by the invention comprises a hydrophobic porous layer, a compact layer and a porous support, wherein the hydrophobic porous layer is back to one side of a tissue to be repaired and is loaded with anti-infective drugs, and the hydrophobicity of the hydrophobic porous layer and the loaded drugs can be matched with each other, so that the composite biological patch is beneficial to slow release of the drugs and plays roles of preventing and resisting infection and preventing adhesion; the porous scaffold has a porous structure, faces one side of the tissue to be repaired, is beneficial to the adhesion and growth of cells and induces the regeneration of membrane tissue; the hydrophobic porous layer and the porous support are separated by the compact layer, so that the dimensional stability and the mechanical strength of a product can be ensured, and meanwhile, the function of a barrier can be played.
In some preferred embodiments, the raw material for preparing the hydrophobic porous layer includes, but is not limited to, hydrophobic nanocellulose, and the preparation of the hydrophobic porous layer using the hydrophobic nanocellulose as the raw material can significantly improve the mechanical properties of the hydrophobic porous layer.
Preferably, the hydrophobic nanocellulose includes, but is not limited to, ethylcellulose.
Ethyl Cellulose (EC) is a water-insoluble cellulose derivative in which hydroxyl groups on the molecule are substituted with a large number of ethyl groups, and unsubstituted hydroxyl groups are connected by hydrogen bonds to form a compact coral-like network structure, giving EC excellent mechanical properties, and its non-toxic, hydrophobic, mechanical, thermoplastic and film-forming properties are of value in many fields such as food, microencapsulation, filtration and medicine. In the invention, the hydrophobic nano-cellulose prepared by taking the ethyl cellulose as the raw material has good mechanical property and hydrophobicity, and can play a role in drug slow release.
In some preferred embodiments, the method of preparing the hydrophobic porous layer comprises the steps of:
dissolving hydrophobic nano-cellulose in an organic reagent, adding an anti-infective drug, and preparing a membrane after mixing;
preferably, the organic reagent includes, but is not limited to, hexafluoroisopropanol and/or ethanol;
preferably, the ratio of the hydrophobic nanocellulose to organic reagent is 1g (4-8) mL, for example, but not limited to, 1g:4mL, 1g:5mL, 1g:6mL, 1g:7mL, or 1g:8 mL;
preferably, the anti-infective agent is added in an amount of 5% -10% by mass of the hydrophobic nanocellulose, such as but not limited to 5%, 6%, 7%, 8%, 9% or 10%;
preferably, the film is formed by methods including but not limited to electrospinning, or other film forming methods known to those skilled in the art;
preferably, the thickness of the hydrophobic porous layer is 0.5-2mm, for example, but not limited to, 0.5mm, 1mm, 1.5mm or 2 mm.
The preparation method of the hydrophobic porous layer is further optimized and adjusted, so that the hydrophobic porous layer has good mechanical properties, can release the medicine slowly, and has the effects of preventing and resisting infection and preventing adhesion.
In some preferred embodiments, the dense layer is made from materials including, but not limited to, ethyl cellulose and/or hydroxypropyl methyl cellulose. The hydroxypropyl methyl cellulose has the advantages of good film forming property, adhesion, oxidation resistance, broad-spectrum antibacterial property, excellent barrier property and the like, the compact layer prepared by taking the hydroxypropyl methyl cellulose as a raw material has good compactness, and meanwhile, the connection strength between the hydroxypropyl methyl cellulose and the hydrophobic porous layer and the porous support can be enhanced. The ethyl cellulose has hydrophobicity, and the connection strength between the dense layer and the hydrophobic porous layer can be improved by using the ethyl cellulose as a raw material to prepare the dense layer.
The term "and/or" means that the preparation material of the dense layer may include ethyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose and hydroxypropyl methyl cellulose.
In some preferred embodiments, the porous scaffold is made of a material including, but not limited to, at least one of type i collagen, cellulose, chitosan, hyaluronic acid, gelatin, silk fibroin, and starch, preferably type i collagen.
The porous scaffold prepared by using the type I collagen as a raw material has a three-dimensional porous structure, is more favorable for cell adhesion and growth, and induces regeneration of membrane tissues. It should be noted that the source of the type I collagen in the present invention is not particularly limited, and commercially available type I collagen or self-prepared type I collagen may be used.
In some preferred embodiments, the method for preparing the porous scaffold comprises the steps of:
dissolving the type I collagen in an acid solution to obtain a collagen solution, and then drying to prepare a porous scaffold;
preferably, the acidic solution includes, but is not limited to, an acetic acid solution and/or a hydrochloric acid solution, preferably an acetic acid solution;
preferably, the concentration of the acetic acid solution is 0.01-1mol/L, such as but not limited to 0.01mol/L, 0.05mol/L, 0.1mol/L, 0.2mol/L, 0.4mol/L, 0.6mol/L, 0.8mol/L or 1mol/L, preferably 0.02-0.5 mol/L;
preferably, the concentration of type i collagen in the collagen solution is between 0.1 wt% and 2.0 wt%, such as but not limited to 0.1 wt%, 0.2 wt%, 0.5 wt%, 1.0 wt%, 1.5 wt% or 2.0 wt%, preferably between 0.5 wt% and 1.5 wt%;
preferably, the drying means includes, but is not limited to, freeze drying, or other drying means known to those skilled in the art;
preferably, the freeze-drying conditions are as follows: treating at-40 deg.c to-10 deg.c for 1-6 hr, treating at-10 deg.c to-0 deg.c for 12-48 hr, and treating at 22 deg.c to 28 deg.c for 1-2 hr.
Preferably, the freeze-drying process conditions are: treating at-30 to-20 deg.c for 1-6 hr, treating at-10 to 0 deg.c for 24-36 hr, and treating at 22-28 deg.c for 1-2 hr.
In the invention, the preparation method of the porous scaffold is further optimized and adjusted, so that the prepared porous scaffold has a good three-dimensional porous structure, and is more favorable for cell adhesion and growth and membrane tissue regeneration induction.
In some preferred embodiments, the method for preparing type I collagen comprises the steps of:
a. removing impurities from the Achilles tendon of the animal, crushing, and then carrying out salt solution treatment. Wherein the impurity removal is to remove excessive impurities such as tissues, fat and the like; the salt solution is treated to remove contaminating proteins. One of the most suitable raw materials for preparing type I collagen is Achilles tendon, and the fibers of the Achilles tendon are almost all type I collagen, so that the steps required for purifying the type I collagen are greatly simplified. Therefore, the invention prepares the type I collagen by using the animal achilles tendon raw material.
b. And (b) performing enzyme treatment on the animal achilles tendon treated in the step (a), and removing insoluble substances. Wherein the enzyme treatment is to remove other impurity proteins; the insoluble matter is mainly large-sized Achilles tendon tissue, and needs to be removed, or the large-sized Achilles tendon can be pulverized again and then treated with enzyme again to improve the utilization rate of the raw material.
c. And c, adjusting the pH value of the solution obtained in the step b to 12-14, and adding a salt solution until the salt concentration in the solution is 2.5-7.5mol/L to obtain a precipitate. The isoelectric precipitation method and the salting-out method are adopted to separate I type collagen precipitate, in addition, the alkaline condition can inactivate the virus well, and the biocompatibility and the safety of the collagen can be improved.
d. And c, sequentially treating the precipitate obtained in the step c with an acidic solution, separating and drying to obtain the type I collagen. And dissolving the precipitate again to remove insoluble impurities, thereby further improving the purity of the type I collagen.
Preferably, the animal achilles tendon comprises but is not limited to at least one of bovine achilles tendon, porcine achilles tendon, equine achilles tendon, and ovine achilles tendon, preferably bovine achilles tendon;
preferably, in step a, the salt solution includes, but is not limited to, NaCl solution, NaHCO solution3At least one of solution, sodium citrate solution, Tris-HCl solution and Tris-Base solution, preferably NaCl solution;
preferably, in step a, the concentration of the salt solution is 5 wt% to 25 wt%, for example, but not limited to, 5%, 10%, 15%, 20% or 25%;
preferably, in the step a, the mass ratio of the animal achilles tendon to the saline solution is 1 (50-100), and can be, but is not limited to, 1:50, 1:60, 1:70, 1:80, 1:90 or 1: 100;
preferably, in the step b, the enzyme treatment is to treat the animal achilles tendon with an acid solution containing enzyme;
preferably, in step b, the enzyme includes but is not limited to at least one of pepsin, trypsin, ficin, bromelain, papain, streptomyces griseus secretase and subtilase, preferably pepsin;
preferably, in step b, the acidic solution includes but is not limited to at least one of acetic acid solution, citric acid solution, malic acid solution and lactic acid solution, preferably acetic acid solution;
preferably, in step b, the concentration of the acidic solution is 0.25-0.8mol/L, such as but not limited to 0.25mol/L, 0.3mol/L, 0.4mol/L, 0.5mol/L, 0.6mol/L, 0.7mol/L or 0.8 mol/L;
preferably, in step c, the pH of the solution obtained in step b is adjusted with a base solution, including but not limited to NaOH, KOH, Ca (OH)2At least one of them, preferablyIs NaOH;
preferably, in the step c, the pH value of the solution obtained in the step b is adjusted to 13, and a salt solution is added to the solution until the salt concentration is 4-5mol/L, under the condition, the collagen separation effect is best.
Preferably, in step d, the acidic solution includes but is not limited to at least one of hydrochloric acid solution, acetic acid solution, citric acid solution, phosphoric acid solution and sulfuric acid solution, preferably hydrochloric acid solution;
preferably, in step d, the concentration of the acidic solution is 0.1-10mol/L, for example, but not limited to, 0.1mol/L, 0.2mol/L, 0.5mol/L, 1mol/L, 2mol/L, 4mol/L, 6mol/L, 8mol/L or 10mol/L, preferably 2-5 mol/L.
The preparation method of the I-type collagen has the following advantages:
1. the animal achilles tendon is taken as a raw material to extract the collagen, the treatment process is simple, and the purity of the collagen is high;
2. the purity of the extracted collagen is high and reaches more than 99 percent, and the triple-helix structure of the collagen is well maintained, so that the collagen has low immunogenicity;
3. the high-purity collagen is the basis and guarantee of the excellent tissue regeneration performance of the product;
4. the virus is well inactivated by an alkali treatment process, so that the extracted collagen has good biocompatibility and safety.
In some preferred embodiments, the anti-infective drug includes, but is not limited to, at least one of ketoprofen, roxithromycin, amoxicillin, or ciprofloxacin, or other anti-infective drugs known to those of skill in the art.
In a second aspect, the invention provides a preparation method of a composite biological patch, which comprises the following steps:
mixing an organic reagent dissolved with ethyl cellulose and a hydroxypropyl methyl cellulose aqueous solution, then coating the mixed solution between the hydrophobic porous layer and the porous bracket, pressing, and heating to obtain a composite biological patch;
preferably, the organic agent includes, but is not limited to, ethanol, or other organic agents known to those skilled in the art;
preferably, the concentration of ethylcellulose in the organic reagent is from 2 wt% to 5 wt%, for example, but not limited to, 2 wt%, 3 wt%, 4 wt%, or 5 wt%;
preferably, the concentration of the hydroxypropyl methylcellulose aqueous solution is 2 wt% to 5 wt%, for example, but not limited to, 2 wt%, 3 wt%, 4 wt%, or 5 wt%;
preferably, the volume ratio of the organic reagent dissolved with the ethyl cellulose and the hydroxypropyl methyl cellulose aqueous solution is 1 (10-15), and can be, but is not limited to, 1:10, 1:11, 1:12, 1:13, 1:14 or 1: 15;
preferably, the pressure of the pressing is 0.4-0.8MPa, such as but not limited to 0.4MPa, 0.5MPa, 0.6MPa, 0.7MPa or 0.8 MPa;
preferably, the pressing time is 40-60min, such as but not limited to 40min, 45min, 50min, 55min or 60 min;
preferably, the temperature of the heating treatment is 110-;
preferably, the time of the heat treatment is 24-36h, for example, but not limited to 24h, 26h, 28h, 30h, 32h, 34h or 36 h;
preferably, the mixed solution is coated to a thickness of 0.1 to 0.5mm, such as but not limited to 0.1mm, 0.2mm, 0.3mm, 0.4mm, 0.5mm, or 0.6 mm;
preferably, the composite biological patch has a thickness of 2-5mm, such as but not limited to 2mm, 3mm, 4mm, 5mm or 6 mm.
In the invention, the preparation method of the composite biological patch is further optimized and adjusted, so that the compactness of the dense layer and the connection strength between the dense layer and the hydrophobic porous layer as well as the porous support are further improved.
In a third aspect, the invention provides a composite biological patch for meninges repair, spinal membrane repair, rotator cuff repair, hernia repair, ophthalmic repair, breast repair, hemostatic repair or oral repair.
The composite biological patch has excellent mechanical property and high flexibility, is easy to be attached to a damaged part, can be free from suture, and can effectively prevent adhesion and induce tissue regeneration; the middle connecting layer and the other two layers have good connecting strength and good compactness, can prevent tissue fluid from leaking and play a role of a barrier; the support layer has good hydrophilicity, the hydrophobic porous layer has good hydrophobicity, and the anti-infection and anti-adhesion effects are good. Can be used as a meningeal patch, rotator cuff patch, hernia patch, ophthalmic patch, breast patch, hemostatic patch, and oral cavity restoration membrane.
The invention is further illustrated by the following specific examples and comparative examples, but it should be understood that these examples are for purposes of illustration only and are not to be construed as limiting the invention in any way.
Example 1
A composite biological patch is prepared by the following steps:
1. preparation of the hydrophobic porous layer: dissolving a certain amount of ethyl cellulose in hexafluoroisopropanol solvent, adding the ethyl cellulose at a ratio of 1g to 6mL, stirring for 36h to prepare a spinning solution with a concentration of 9.5%, then adding the anti-infective drug ketoprofen at a ratio of 8% of the ethyl cellulose, and then continuously stirring for 60h to obtain the spinning solution containing the anti-infective drug. And (2) putting the spinning solution into an injector, connecting a needle head with high pressure, adopting an aluminum foil as a receiving device, setting the spinning voltage at 15kV, the spinning speed at 0.3mL/h, the receiving distance at 15cm and the spinning time at 3h to obtain a cellulose nanofiber membrane with the thickness of 1mm, then placing the obtained nanofiber membrane in a vacuum oven, drying at 80 ℃ overnight, and removing the residual solvent.
2. Preparation of type I collagen porous scaffold:
preparation of type i collagen: weighing a certain weight of fresh bovine achilles tendon material, pretreating, sufficiently removing redundant tissues, fat and other impurities, sufficiently crushing the treated bovine achilles tendon, soaking in a 15% sodium chloride solution (mass ratio of bovine achilles tendon to salt solution: 1:75) for 6 hours, washing with sterilized distilled water for several times, and centrifuging to obtain the pretreated bovine achilles tendon;
suspending the treated Achilles tendon in acetic acid solution (acetic acid concentration is 0.5mol/L) of enzyme for extraction, and fully extracting collagen by adopting special stirring and cooling equipment in the extraction process and maintaining the temperature at a lower value. Centrifuging after stirring and extracting for 1h to remove the precipitate, preserving the supernatant, then crushing the removed precipitate again and stirring for 1h, centrifuging again and removing the precipitate, continuously repeating the process to carry out re-extraction, and obtaining the supernatant again and preserving;
adjusting the pH of the obtained supernatant to be 13 by adopting a sodium hydroxide solution, then adding a NaCl solution until the concentration of NaCl in the solution is 4mol/L, stirring for 33h, and centrifuging to obtain a precipitate, namely a high-purity collagen semi-finished product;
and (3) putting the obtained semi-finished product into a 3mol/L acetic acid solution for neutralization for 24 hours, and then filtering and drying the semi-finished product to obtain a high-purity type I collagen finished product (the purity is over 99 percent).
Preparation of collagen solution: dissolving high-purity I type collagen in 0.6mol/L acetic acid solution, and strongly stirring for 24h to obtain 1% uniform collagen solution;
freeze-drying of collagen solution: the collagen solution obtained was freeze-dried.
And (3) a freeze drying process: firstly, putting a collagen solution into a freezing chamber (the temperature is-30 ℃ to-20 ℃) for freezing for 3 hours, then raising the temperature of the freezing chamber to keep the temperature between-10 ℃ and 0 ℃ for 30 hours, after the collagen solution is frozen and dried to a certain degree, gradually raising the temperature in the freezing and drying chamber to the room temperature, keeping the temperature for 1.5 hours, and taking out the collagen solution to obtain the collagen scaffold material with the bionic three-dimensional porous structure.
3. Preparation of a film patch: preparation of the tie layer solution: weighing a certain amount of ethyl cellulose, dissolving the ethyl cellulose in an absolute ethyl alcohol solution, wherein the solution concentration is 3%, simultaneously weighing a certain amount of hydroxypropyl methyl cellulose, dissolving the hydroxypropyl methyl cellulose in water, wherein the solution concentration is 3%, then mixing the ethyl cellulose solution and the hydroxypropyl methyl cellulose solution (the mass ratio of the ethyl cellulose solution to the hydroxypropyl methyl cellulose solution is 1:12), coating a layer of mixed solution with the thickness of 0.3mm on the surface of a cellulose nano-cellulose membrane after mixing, then placing a collagen porous support on the mixed solution, pressing for 50min under the pressure of 0.6MPa, and then placing the mixed solution in a vacuum oven for heat treatment (the temperature is 120 ℃, and the time is 30h), thus obtaining the membrane patch with excellent mechanical property, anti-infection property and good induced tissue regeneration property.
Example 2
A composite biological patch is prepared by the following steps:
1. preparation of the hydrophobic porous layer: dissolving a certain amount of ethyl cellulose in absolute ethyl alcohol serving as a solvent, adding the ethyl cellulose at a ratio of 1g to 4mL, stirring for 24-48h to prepare a spinning solution with the concentration of 24.1%, then adding the anti-infective drug ketoprofen, adding the ethyl cellulose at a ratio of 5%, and then continuously stirring for 48h to obtain the spinning solution containing the anti-infective drug. And (2) putting the spinning solution into an injector, connecting a needle head with high pressure, adopting an aluminum foil as a receiving device, setting the spinning voltage to 10kV, setting the spinning speed to 0.1mL/h, setting the receiving distance to 13cm and the spinning time to 1h to obtain a cellulose nanofiber membrane with the thickness of 0.5mm, then placing the obtained nanofiber membrane in a vacuum oven to dry overnight at 80 ℃, and removing the residual solvent.
2. Preparation of type I collagen porous scaffold:
type I collagen was prepared as in example 1.
Preparation of collagen solution: dissolving high-purity I type collagen in 0.025mol/L hydrochloric acid solution, and strongly stirring for 24h to obtain uniform collagen solution with the concentration of 0.1%;
freeze-drying of collagen solution: the collagen solution obtained was freeze-dried.
And (3) a freeze drying process: firstly, putting a collagen solution into a freezing chamber (the temperature is minus 40 ℃ to minus 20 ℃) for freezing for 1h, then raising the temperature of the freezing chamber to keep the temperature between minus 10 ℃ and 0 ℃, keeping the time for 12h, preferably 24h, after the collagen solution is frozen and dried to a certain degree, gradually keeping the temperature in the freezing and drying chamber to the room temperature, keeping the temperature for 1h, and taking out the collagen solution to obtain the collagen scaffold material with the bionic three-dimensional porous structure.
3. Preparation of a film patch: preparation of the tie layer solution: weighing a certain amount of ethyl cellulose, dissolving the ethyl cellulose in an absolute ethyl alcohol solution, wherein the solution concentration is 2%, simultaneously weighing a certain amount of hydroxypropyl methyl cellulose, dissolving the hydroxypropyl methyl cellulose in water, wherein the solution concentration is 2%, then mixing the ethyl cellulose solution and the hydroxypropyl methyl cellulose solution (the mass ratio of the ethyl cellulose solution to the hydroxypropyl methyl cellulose solution is 1:10), coating a layer of mixed solution with the thickness of 0.1mm on the surface of a cellulose nano-cellulose membrane after mixing, then placing a collagen porous support on the mixed solution, pressing for 40min at the pressure of 0.4MPa, and then placing the mixed solution in a vacuum oven for heat treatment (the temperature is 110 ℃, and the time is 24h), thus obtaining the membrane patch with excellent mechanical property, anti-infection property and good induced tissue regeneration.
Example 3
A composite biological patch is prepared by the following steps:
1. preparation of the hydrophobic porous layer: dissolving a certain amount of ethyl cellulose in a hexafluoroisopropanol solvent as a solvent, adding the ethyl cellulose at a ratio of 1g to 8mL, stirring for 48 hours to prepare a spinning solution with a concentration of 7.3%, then adding the anti-infective drug ketoprofen at a ratio of 10% of the ethyl cellulose, and then continuously stirring for 72 hours to obtain the spinning solution containing the anti-infective drug. And (2) putting the spinning solution into an injector, connecting a needle head with high pressure, setting a receiving device to be an aluminum foil, setting the spinning voltage to be 20kV, the spinning speed to be 0.5mL/h, the receiving distance to be 20cm and the spinning time to be 4h, obtaining a cellulose nano-fiber membrane with the thickness of 2mm, then placing the obtained nano-fiber membrane in a vacuum oven, drying at 80 ℃ overnight, and removing the residual solvent.
2. Preparation of type I collagen porous scaffold:
type I collagen was prepared as in example 1.
Preparation of collagen solution: dissolving high-purity I-type collagen in 1mol/L acetic acid solution, strongly stirring for 24h to obtain uniform collagen solution with the concentration of 2.0%, and then vacuumizing the collagen solution to fully remove bubbles in the solution;
freeze-drying of collagen solution: the collagen solution obtained was freeze-dried.
And (3) a freeze drying process: firstly, putting a collagen solution into a freezing chamber (the temperature is-20 ℃ to-10 ℃) for freezing for 6 hours, then raising the temperature of the freezing chamber to keep the temperature between-10 ℃ and 0 ℃, keeping the time for 48 hours, preferably 36 hours, after the collagen solution is freeze-dried to a certain degree, gradually keeping the temperature in the freeze-drying chamber to the room temperature, keeping the temperature for 2 hours, and taking out the collagen solution to obtain the collagen scaffold material with the bionic three-dimensional porous structure.
3. Preparation of a film patch: preparation of the tie layer solution: weighing a certain amount of ethyl cellulose, dissolving the ethyl cellulose in an absolute ethyl alcohol solution, wherein the solution concentration is 5%, simultaneously weighing a certain amount of hydroxypropyl methyl cellulose, dissolving the hydroxypropyl methyl cellulose in water, wherein the solution concentration is 5%, then mixing the ethyl cellulose solution and the hydroxypropyl methyl cellulose solution (the mass ratio of the ethyl cellulose solution to the hydroxypropyl methyl cellulose solution is 1:15), coating a layer of mixed solution with the thickness of 0.5mm on the surface of a cellulose nano-cellulose membrane after mixing, then placing a collagen porous support on the mixed solution, pressing for 60min at the pressure of 0.8MPa, and then placing the mixed solution in a vacuum oven for heat treatment (the temperature is 130 ℃, and the time is 36h), thus obtaining the membrane patch with excellent mechanical property, anti-infection property and good induced tissue regeneration property.
Comparative example 1
A biological patch is different from example 1 in that only a type I collagen porous scaffold is prepared, and the prepared porous scaffold is pressed for 50min at a pressure of 0.6MPa and then placed in a vacuum oven for heat treatment (temperature: 120 ℃ C., time is 30h) to obtain a membrane patch.
Comparative example 2
A composite biological patch differing from example 1 in that the hydrophobic porous layer is not loaded with an anti-inflammatory drug.
Comparative example 3
A composite biological patch, which is different from the composite biological patch in example 1 in that a hydrophobic porous layer is replaced by a hydrophilic nanocellulose porous layer, and the hydrophilic nanocellulose porous layer is prepared by the following method:
dissolving a certain amount of cellulose acetate in a mixed solvent of acetone and N, N-dimethylacetamide (the volume ratio of the acetone to the N, N-dimethylacetamide is 1:1), adding 1g to 8mL, stirring for 36h to prepare a spinning solution with the concentration of 12.6%, then adding the anti-infective drug ketoprofen, adding 8% of ethyl cellulose, and continuing stirring for 60h to obtain the spinning solution containing the anti-infective drug. And (2) putting the spinning solution into an injector, connecting a needle head with high pressure, adopting an aluminum foil as a receiving device, setting the spinning voltage at 15kV, the spinning speed at 0.3mL/h, the receiving distance at 15cm and the spinning time at 3h to obtain a cellulose nanofiber membrane with the thickness of 1mm, then placing the obtained nanofiber membrane in a vacuum oven, drying at 80 ℃ overnight, and removing the residual solvent.
Test example 1
1. Drug release rate: 200mg of the membrane patches of examples 1, 2 and 3 and comparative example 3 were immersed in 50mL of PBS buffer solution with pH value of 7, placed on a shaker, 5mL of the solution was taken out at 1h, 5h, 24h, 48h, 72h, 120h, 168h and 336h, respectively, while the corresponding volume of PBS buffer solution was supplemented, and then the absorbance of the taken-out solution at the corresponding UV wavelength of the drug was measured using a UV-visible spectrophotometer. Then preparing drug solutions with different concentrations, carrying out absorbance test under corresponding concentrations, drawing a drug concentration-absorbance standard curve according to test results, and calculating the in-vitro cumulative release rate of the drug according to the standard curve, wherein the test results are shown in figure 1.
According to the test result of the accumulative release rate, the anti-infective medicament is in the hydrophobic porous layer, so that the medicament in the membrane patch of the embodiment is slowly released, the accumulative release rate reaches the highest and reaches the balance basically at the 7 th day, and the highest accumulative release rate can reach about 60 percent; in contrast, in the membrane patch of comparative example 3, the porous layer is hydrophilic, so the initial release rate is faster, the highest release rate is reached and balanced within 48h, and the cumulative release rate reaches about 80%, thus the hydrophobicity of the porous layer is favorable for the slow release of the drug, so the aim of continuously resisting infection is achieved.
2. Mechanical properties: the samples were cut into 20mm wide bars for tensile testing according to the method in GBT3923.1-2013, and the test results are shown in the following table.
Tensile Strength (MPa) | Elongation at Break (%) | |
Example 1 | 5.35±1.21 | 18.35±2.33 |
Example 2 | 4.76±2.01 | 15.67±2.51 |
Example 3 | 5.93±1.88 | 22.17±1.89 |
Comparative example 1 | 1.02±0.58 | 7.23±1.93 |
Comparative example 2 | 5.23±2.10 | 17.79±2.45 |
Comparative example 3 | 5.12±2.69 | 17.98±3.01 |
According to test results, the preparation of the intermediate dense layer and the hydrophobic porous layer has a large influence on the mechanical properties of the membrane patch, the mechanical properties of the membrane patch can be obviously improved along with the introduction of the dense layer and the hydrophobic porous layer, and the tensile strength of the membrane patch is higher when the proportion of the hydroxypropyl cellulose solution in the intermediate dense layer is larger, so that the prepared membrane patch has excellent mechanical properties compared with a common collagen scaffold.
3. Tissue regeneration induction and adhesion prevention:
a new Zealand white rabbit was used as a model, a 4 cm-long wound was cut at the dural defect site, then the membrane patches provided in example 1 and comparative example 3 were implanted, corresponding tissue specimens were subjected to HE staining at 6 months, and tissue regeneration and adhesion were observed, with the results of example 1 and comparative example 3 shown in FIG. 2 and FIG. 3, respectively. Wherein A is brain tissue and the arrow indicates a patch of membrane.
As can be seen from the pictures, after 6 months, the patch implanted in example 1 found that new dural tissue had grown instead of the original implant, and the dural defect site had no significant adhesion to the brain tissue and no significant inflammatory response. The patch implanted in comparative example 3 also has new dura mater tissue growth, but due to the good hydrophilicity of the porous layer, adhesion is easy to occur, so that the new tissue is tightly connected to the brain tissue, and other diseases such as tumor are easy to cause.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
1. The composite biological patch is characterized by comprising a hydrophobic porous layer, a compact layer and a porous support;
the hydrophobic porous layer is back to one side of the tissue to be repaired and is loaded with anti-infective drugs;
the side of the porous bracket facing the tissue to be repaired;
the dense layer is located between the hydrophobic porous layer and the porous scaffold.
2. The composite biological patch as claimed in claim 1, wherein the preparation raw material of the hydrophobic porous layer comprises hydrophobic nanocellulose;
preferably, the hydrophobic nanocellulose comprises ethylcellulose.
3. The composite biological patch as claimed in claim 2, wherein the preparation method of the hydrophobic porous layer comprises the steps of:
dissolving hydrophobic nano-cellulose in an organic reagent, adding an anti-infective drug, and preparing a membrane after mixing;
preferably, the organic reagent comprises hexafluoroisopropanol and/or ethanol;
preferably, the ratio of the hydrophobic nanocellulose to the organic reagent is 1g (4-8) mL;
preferably, the anti-infective drug is added in an amount of 5-10% of the hydrophobic nano-cellulose in percentage by mass;
preferably, the film-making manner comprises electrostatic spinning;
preferably, the thickness of the hydrophobic porous layer is 0.5-2 mm.
4. The composite biological patch as claimed in claim 1, wherein the preparation material of the dense layer comprises ethyl cellulose and/or hydroxypropyl methyl cellulose.
5. The composite biological patch as claimed in claim 1, wherein the porous scaffold is made of at least one material selected from type I collagen, cellulose, chitosan, hyaluronic acid, gelatin, silk fibroin and starch, and preferably type I collagen.
6. The composite biological patch according to claim 5, wherein the preparation method of the porous scaffold comprises the following steps:
dissolving the type I collagen in an acid solution to obtain a collagen solution, and then drying to prepare a porous scaffold;
preferably, the acidic solution comprises an acetic acid solution and/or a hydrochloric acid solution, preferably an acetic acid solution;
preferably, the concentration of the acetic acid solution is 0.01-1mol/L, preferably 0.02-0.5 mol/L;
preferably, the concentration of the type I collagen in the collagen solution is 0.1 wt% to 2.0 wt%, preferably 0.5 wt% to 1.5 wt%;
preferably, the manner of drying comprises freeze drying;
preferably, the freeze-drying conditions are as follows: treating at-40 deg.c to-10 deg.c for 1-6 hr, treating at-10 deg.c to-0 deg.c for 12-48 hr, and treating at 22 deg.c to 28 deg.c for 1-2 hr.
7. The composite biological patch according to claim 5, wherein the preparation method of the type I collagen comprises the following steps:
a. removing impurities from the Achilles tendon of the animal, crushing, and then carrying out salt solution treatment;
b. treating the animal achilles tendon treated in the step a with enzyme, and removing insoluble substances;
c. b, adjusting the pH value of the solution obtained in the step b to 12-14, and adding a salt solution until the salt concentration in the solution is 2.5-7.5mol/L to obtain a precipitate;
d. c, sequentially treating the precipitate obtained in the step c with an acidic solution, separating and drying to obtain type I collagen;
preferably, the animal achilles tendon comprises at least one of bovine achilles tendon, porcine achilles tendon, equine achilles tendon and ovine achilles tendon, preferably bovine achilles tendon;
preferably, in step a, the salt solution comprises NaCl solution and NaHCO solution3At least one of solution, sodium citrate solution, Tris-HCl solution and Tris-Base solution, preferably NaCl solution;
preferably, in the step a, the concentration of the salt solution is 5 wt% to 25 wt%;
preferably, in the step a, the mass ratio of the animal achilles tendon to the saline solution is 1 (50-100);
preferably, in the step b, the enzyme treatment is to treat the animal achilles tendon with an acid solution containing enzyme;
preferably, in the step b, the enzyme comprises at least one of pepsin, trypsin, ficin, bromelain, papain, streptomyces griseus secretase and subtilisin, and is preferably pepsin;
preferably, in the step b, the acidic solution comprises at least one of an acetic acid solution, a citric acid solution, a malic acid solution and a lactic acid solution, and is preferably an acetic acid solution;
preferably, in the step b, the concentration of the acid solution is 0.25-0.8 mol/L;
preferably, in step c, the pH of the solution obtained in step b is adjusted by using alkali solution, wherein the alkali comprises NaOH, KOH, Ca (OH)2Preferably NaOH;
preferably, in the step c, the pH value of the solution obtained in the step b is adjusted to 13, and a salt solution is added until the salt concentration in the solution is 4-5 mol/L;
preferably, in the step d, the acidic solution includes at least one of a hydrochloric acid solution, an acetic acid solution, a citric acid solution, a phosphoric acid solution and a sulfuric acid solution, and is preferably a hydrochloric acid solution;
preferably, in step d, the concentration of the acidic solution is 0.1-10mol/L, preferably 2-5 mol/L.
8. The composite biological patch as claimed in claim 1, wherein the anti-infective drug comprises at least one of ketoprofen, roxithromycin, amoxicillin or ciprofloxacin.
9. The method for preparing the composite biological patch as claimed in claim 4, wherein the method comprises the following steps:
mixing an organic reagent dissolved with ethyl cellulose and a hydroxypropyl methyl cellulose aqueous solution, then coating the mixed solution between the hydrophobic porous layer and the porous bracket, pressing, and heating to obtain a composite biological patch;
preferably, the organic reagent comprises ethanol;
preferably, the concentration of ethyl cellulose in the organic reagent is 2 wt% to 5 wt%;
preferably, the concentration of the hydroxypropyl methyl cellulose aqueous solution is 2 wt% -5 wt%;
preferably, the volume ratio of the organic reagent dissolved with the ethyl cellulose to the hydroxypropyl methyl cellulose aqueous solution is 1 (10-15);
preferably, the pressure of the pressing is 0.4-0.8 MPa;
preferably, the pressing time is 40-60 min;
preferably, the temperature of the heating treatment is 110-;
preferably, the time of the heat treatment is 24-36 h;
preferably, the thickness of the mixed solution coating is 0.1-0.5 mm;
preferably, the thickness of the composite biological patch is 2-5 mm.
10. Use of a composite biological patch according to any one of claims 1 to 8 or a composite biological patch prepared by the method of manufacture according to claim 9 in meningeal repair, rotator cuff repair, hernia repair, ophthalmic repair, breast repair, haemostatic repair or oral repair.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110964615.6A CN113663137B (en) | 2021-08-19 | 2021-08-19 | Composite biological patch and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110964615.6A CN113663137B (en) | 2021-08-19 | 2021-08-19 | Composite biological patch and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113663137A true CN113663137A (en) | 2021-11-19 |
CN113663137B CN113663137B (en) | 2022-12-06 |
Family
ID=78544762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110964615.6A Active CN113663137B (en) | 2021-08-19 | 2021-08-19 | Composite biological patch and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113663137B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114377201A (en) * | 2022-01-19 | 2022-04-22 | 福州市第二医院(福建省福州中西医结合医院、福州市职业病医院) | Rotator cuff patch based on cellulose gelatin coating and preparation method thereof |
CN114732949A (en) * | 2022-03-25 | 2022-07-12 | 上海工程技术大学 | Rotator cuff patch with oriented structure and preparation method thereof |
CN114887119A (en) * | 2022-05-09 | 2022-08-12 | 浙江大学医学院附属第一医院 | High-molecular artificial dura mater with anti-infection capacity and preparation method thereof |
CN116688248A (en) * | 2023-06-20 | 2023-09-05 | 湖南大学 | A kind of anti-tissue adhesion film and its preparation method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104857561A (en) * | 2015-04-21 | 2015-08-26 | 世科志扬(北京)医疗科技有限公司 | High-strength bionic collagen membrane and preparation method thereof |
CN106693059A (en) * | 2016-12-28 | 2017-05-24 | 广州迈普再生医学科技有限公司 | Composite tissue repair patch and preparation method and application thereof |
WO2017216609A1 (en) * | 2016-06-15 | 2017-12-21 | Tubitak | Multifunctional hernia patch |
CN113144294A (en) * | 2021-02-20 | 2021-07-23 | 北京邦塞科技有限公司 | Preparation method of three-dimensional porous collagen scaffold, double-layer collagen scaffold, preparation method and application |
-
2021
- 2021-08-19 CN CN202110964615.6A patent/CN113663137B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104857561A (en) * | 2015-04-21 | 2015-08-26 | 世科志扬(北京)医疗科技有限公司 | High-strength bionic collagen membrane and preparation method thereof |
WO2017216609A1 (en) * | 2016-06-15 | 2017-12-21 | Tubitak | Multifunctional hernia patch |
CN106693059A (en) * | 2016-12-28 | 2017-05-24 | 广州迈普再生医学科技有限公司 | Composite tissue repair patch and preparation method and application thereof |
CN111840648A (en) * | 2016-12-28 | 2020-10-30 | 广州迈普再生医学科技股份有限公司 | Multilayer composite tissue repair patch and preparation method thereof |
CN113144294A (en) * | 2021-02-20 | 2021-07-23 | 北京邦塞科技有限公司 | Preparation method of three-dimensional porous collagen scaffold, double-layer collagen scaffold, preparation method and application |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114377201A (en) * | 2022-01-19 | 2022-04-22 | 福州市第二医院(福建省福州中西医结合医院、福州市职业病医院) | Rotator cuff patch based on cellulose gelatin coating and preparation method thereof |
CN114732949A (en) * | 2022-03-25 | 2022-07-12 | 上海工程技术大学 | Rotator cuff patch with oriented structure and preparation method thereof |
CN114732949B (en) * | 2022-03-25 | 2023-01-24 | 上海工程技术大学 | Rotator cuff patch with oriented structure and method of making the same |
CN114887119A (en) * | 2022-05-09 | 2022-08-12 | 浙江大学医学院附属第一医院 | High-molecular artificial dura mater with anti-infection capacity and preparation method thereof |
CN116688248A (en) * | 2023-06-20 | 2023-09-05 | 湖南大学 | A kind of anti-tissue adhesion film and its preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
CN113663137B (en) | 2022-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113663137B (en) | Composite biological patch and preparation method and application thereof | |
Cao et al. | Double crosslinked HLC-CCS hydrogel tissue engineering scaffold for skin wound healing | |
US6949625B2 (en) | Injectable implant of insoluble globin | |
EP3072536B1 (en) | Hydrophilic electrospinning biological composite stent material used for tissue regeneration and preparation method and application thereof | |
CN101695581A (en) | Method for preparing human-like collagen haemostatic sponge in scale | |
CN106039416A (en) | Chitosan-sericin composite biological scaffold as well as preparation method and application thereof | |
CN1423568A (en) | Use of soluble cellulose derivative having been made hardly soluble in water and process for producing the same | |
CN107823699B (en) | Hemostatic anti-adhesion membrane and preparation method thereof | |
CN106913907B (en) | Preparation method of cell growth scaffold with structural memory characteristic | |
CN100368534C (en) | Biologically derived amniotic membrane, composite biologically derived amniotic membrane and preparation method thereof | |
CN104740683A (en) | Cornea repair material with double-layer structure and preparation method of cornea repair material | |
CN104548201B (en) | A kind of corneal tissue repair material and preparation method thereof | |
CN114225113B (en) | Degradable artificial dura mater with double-layer structure and preparation method thereof | |
US20160367724A1 (en) | Pepsinized collagen implants and biomedical uses thereof | |
CN108853581B (en) | High-molecular polymer hydrogel composite Medpor prosthetic eye holder and preparation method thereof | |
JP4642765B2 (en) | Insoluble globin injectable implants | |
JPWO2003094985A1 (en) | Artificial extracellular matrix and method for producing the same | |
CN104758983B (en) | Preparation method and application of bFGF-loaded fish collagen-based composite material | |
WO2018090341A1 (en) | Artificial composite membrane and preparation method and use thereof | |
CN108619552B (en) | Absorbable wound repair material for adsorbing GGTAl gene knockout pig collagen and preparation method thereof | |
US10052400B2 (en) | Method for preparing neutralized matrix of non-antigenic collagenous material | |
CN116082717B (en) | Hydrogel, vascular fiber skeleton, preparation method and application thereof | |
JP2009513290A (en) | Scleral buckling band and manufacturing method thereof | |
RU2836308C1 (en) | Collagen-containing hydrogel from human bone tissue and method for its preparation | |
CN210698333U (en) | Biological mesh for repairing soft tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |